EN DE
STOCK COMPARISON

Genscript Biotech vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Genscript Biotech (1548) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 14, 2026.

As of Aug 14, 2026, Fair Value Calculator sees Genscript Biotech as the less overvalued of the two: Genscript Biotech trades at HK$24.88 versus a fair value of HK$15.14 (-39%), while Vertex Pharmaceuticals trades at $516 versus $279 (-46%).
Genscript Biotech
1548.HK · HKD · Health Care
-39%
upside to fair value
overvalued
PriceHK$24.88
Fair ValueHK$15.14
Quality55/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-46%
upside to fair value
overvalued
Price$516
Fair Value$279
Quality79/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Genscript BiotechVertex Pharmaceuticals
Valuation
P/E (TTM)28.8×
3.55×P/S (TTM)10.06×
0.86×P/B6.59×
10.2×EV/EBITDA23.8×
PEG1.72×
Profitability
-56%Net margin36%
17%Operating margin38%
-13%Return on equity24%
3%Return on assets12%
Growth
43%Revenue growth (YoY)8%
15.3%Avg. growth/yr (3Y)10.6%
19.7%Avg. growth/yr (5Y)14.2%
Balance & size
Debt / equity0.03×
$3BMarket cap$123B
mixedGrowth qualityhealthy

Genscript Biotech leads: 6 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Genscript Biotechof which business quality 59 · market factors 65 Vertex Pharmaceuticalsof which business quality 77 · market factors 73
ProfitabilityMargins and returns on capital today
5
72
Quality GrowthAre margins and returns improving?
79
65
CashflowEarnings quality: real cash, not paper profit
89
79
Fin. StrengthBalance sheet, leverage, solvency risk
82
92
InvestmentDisciplined investing over empire-building
21
58
Low VolatilityCalm price path (market factor)
39
86
MomentumPrice trend over the last 3–12 months (market factor)
67
60
52W MomentumDistance to the 52-week high (market factor)
90
80
Net IssuanceBuybacks instead of dilution
71
82

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Genscript Biotech

DCF ModelsHK$3.03
Earnings-BasedHK$1.06
MultiplesHK$2.07
Asset-BasedHK$1.21
Growth DCFHK$2.92
Economic ProfitHK$1.06

13 of 13 models see the stock below the current price.

Vertex Pharmaceuticals

DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692

21 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Genscript Biotech
Bear HK$11.30Fair Value HK$15.14Bull HK$19.07
HK$24.88 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$516 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Genscript Biotech · Health Care

Quality score55 · above median
Fair value upside-39% · below median

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-46% · below median

Bottom line

As of Aug 14, 2026, Fair Value Calculator sees Genscript Biotech as the less overvalued of the two: Genscript Biotech trades at HK$24.88 versus a fair value of HK$15.14 (-39%), while Vertex Pharmaceuticals trades at $516 versus $279 (-46%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.